In Vitro Characterization of a Sustained-Release Formulation for Enfuvirtide | Zendy

Sam N. Rothstein | Zendy; Kelly Huber | Zendy; Nicolas SluisCremer | Zendy; Steven R. Little | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

In Vitro Characterization of a Sustained-Release Formulation for Enfuvirtide

Author(s) -

Sam N. Rothstein,

Kelly Huber,

Nicolas SluisCremer,

Steven R. Little

Publication year - 2013

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.02440-13

Subject(s) - enfuvirtide , dosing , pharmacology , drug , human immunodeficiency virus (hiv) , food and drug administration , medicine , pharmacokinetics , chemistry , virology , immunology , gp41 , epitope , antigen

Although approved by the U.S. Food and Drug Administration, enfuvirtide is rarely used in combination antiretroviral therapies (cART) to treat HIV-1 infection, primarily because of its intense dosing schedule that requires twice-daily subcutaneous injection. Here, we describe the development of enfuvirtide-loaded, degradable poly(lactic-co-glycolic) acid microparticles that provide linear in vitro release of the drug over an 18-day period. This sustained-release formulation could make enfuvirtide more attractive for use in cART.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research